Clinicaltrials.gov identifier:
NCT05129605
Prevention
People at high risk for prostate cancer due to an inherited mutation
Study Contact Information:
For additional information, please contact:
Olympia Price by phone: 857-238-3838
or by email: oprice@partners.org
Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)
About the Study
This study will look at how enhanced cancer screening using will improve early detection rates and further understanding of how inherited mutations can lead to development of cancer.
What the Study Involves
Two groups of patients will be enrolled in this study:
- One group will enroll people who have an in one of the following genes: , ATR, , , , , , FANCA, GEN1, , , , , , , , , ,
- The other study group will enroll people who do not have an inherited genetic mutation, but who do have a strong family history suggestive of increased risk for cancer.
Both study groups will receive the same cancer screening tests:
- physical exam (digital rectal exam)
- prostate-specific antigen () test
- of the .
Study participants will be followed for up to 20 years.
Study Location
Massachusetts
- Boston, MA
Massachusetts General Hospital
Lead Researcher: Keyan Salari, MD, PhD
Study coordinator: Olympia Price: 857-238-3838 or oprice@partners.org
Men age 35-74 years old who meet the following criteria may be eligible:
- No prior diagnosis of cancer
- Meets either group 1 or group 2 criteria:
- Group 1: has an in one of the following genes: , ATR, , , , , , FANCA, GEN1, , , , , , , , , , .
- Group 2: has a strong family history suggestive of high genetic risk for cancer but with no inherited genetic mutation.
Men are not eligible to participate if they:
- have had a prior diagnosis or treatment of cancer
- are not able to undergo a MRI or receive the contrast agent